Clinical production and therapeutic applications of alloreactive natural killer cells

Methods in Molecular Biology

Volumn 882, Issue , 2012, Pages 491-507

  McKenna, David H ^a   Kadidlo, Diane M ^b   Cooley, Sarah ^b   Miller, Jeffrey S ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cell processing; Current good manufacturing practices; Immunotherapy; NK cells

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; NATURAL KILLER CELL RECEPTOR;

ADOPTIVE TRANSFER; ADVANCED CANCER; ALLOIMMUNITY; ARTICLE; BIOLOGY; CLINICAL DECISION MAKING; HEMATOPOIETIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LEUKAPHERESIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROCESSING; QUALITY CONTROL; SOLID TUMOR; TRANSPLANTATION; ALLOTRANSPLANTATION; CYTOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; TRANSPLANTATION, HOMOLOGOUS;

EID: 84867389253     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-842-9_28     Document Type: Article

References (76)

1. Herberman RB, Ortaldo JR (1981) Natural killer cells: their roles in defenses against disease. Science 214(4516):24-30
2. Kiessling R, Petranyi G, Klein G, Wigzel H (1975) Genetic variation of in vitro cytolytic activity and in vivo rejection potential of nonimmunized semi-syngeneic mice against a mouse lymphoma line. Int J Cancer 15(6):933-940
3. Moretta L, Ferlazzo G, Bottino C, Vitale M, Pende D, Mingari MC et al (2006) Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 214:219-228
4. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E (2005) Natural-killer cells and dendritic cells: "l'union fait la force". Blood 106(7):2252-2258
5. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22(11):633-640
6. Fehniger TA, Caligiuri MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97(1):14-32
7. Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461-469
8. Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA (1985) Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer 55(6):1327-1333
9. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R et al (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180(4): 1395-1403
10. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3(2):133-146
11. Young HA, Ortaldo J (2006) Cytokines as critical co-stimulatory molecules in modulating the immune response of natural killer cells. Cell Res 16(1):20-24
12. Singh SM, Yanagawa H, Hanibuchi M, Miki T, Okamura H, Sone S (2000) Augmentation by interleukin-18 of MHC-nonrestricted killer activity of human peripheral blood mononuclear cells in response to interleukin-12. Int J Immunopharmacol 22(1):35-43
13. Ljunggren HG, Karre K (1990) In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 11(7):237-244
14. Vales-Gomez M, Reyburn HT, Mandelboim M, Strominger JL (1998) Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity 9(3):337-344
15. Houchins JP, Yabe T, McSherry C, Bach FH (1991) DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 173(4):1017-1020
16. Lopez-Botet M, Angulo A, Guma M (2004) Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens 63(3):195-203
17. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A (2006) Surface NK receptors and their ligands on tumor cells. Semin Immunol 18(3):151-158
18. Meyaard L (2008) The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol 83(4):799-803
19. Riteau B, Menier C, Khalil-Daher I, Martinozzi S, Pla M, Dausset J et al (2001) HLA-G1 coexpression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 13(2): 193-201
20. Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED (2001) HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigenspeci ficCTL cytolysis. J Immunol 166(8): 5018-5026
21. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM et al (2003) Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA 100):8856-8861
22. Cerboni C, Achour A, Warnmark A, Mousavi-Jazi M, Sandalova T, Hsu ML et al (2006) Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR-1/ILT2/CD85j. Eur J Immunol 36(3):732-741
23. Kirwan SE, Burshtyn DN (2005) Killer cell Ig-like receptor-dependent signaling by Ig-like transcript 2 (ILT2/CD85j/LILRB1/LIR-1). J Immunol 175(8):5006-5015
24. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA et al (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity 25(2):331-342
25. Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, Bergmann TL et al (2007) A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self MHC is developmentally immature. Blood 110:578-586
26. Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, Parham P (2003) Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 101(9):3730-3740
27. Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ et al (2005) KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106(13):4370-4376
28. Bottino C, Castriconi R, Moretta L, Moretta A (2005) Cellular ligands of activating NK receptors. Trends Immunol 26(4):221-226
29. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V et al (2009) ATM-ATR dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK cell susceptibility and is associated with a senescent phenotype. Blood 113(15):3503-3511
30. Stein MN, Shin J, Gudzowaty O, Bernstein AM, Liu JM (2006) Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. Anticancer Res 26(3A):1759-1763
31. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A et al (2005) Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105(5):2066-2073
32. Re F, Staudacher C, Zamai L, Vecchio V, Bregni M (2006) Killer cell Ig-like receptors ligandmismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer 107(3):640-648
33. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M et al (2005) Natural killer cell-mediated lysis of hepatoma cells via speci ficinduction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65(14):6321-6329
34. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N et al (2008) NKG2Ddeficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28(4):571-580
35. Brenner CD, King S, Przewoznik M, Wolters I, Adam C, Bornkamm GW et al (2010) Requirements for control of B-cell lymphoma by NK cells. Eur J Immunol 40(2):494-504
36. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097-2100
37. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8): 3051-3057
38. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS et al (2002) Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100(10):3825-3827
39. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA et al (2006) The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 12(8):876-884
40. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL et al (2007) Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109(11):5058-5061
41. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285(5426):412-415
42. Lundqvist A, McCoy JP, Samsel L, Childs R (2007) Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 109(8):3603-3606
43. Russell JH, Ley TJ (2002) Lymphocytemediated cytotoxicity. Annu Rev Immunol 20:323-370
44. Murphy WJ, Keller JR, Harrison CL, Young HA, Longo DL (1992) Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 80(3):670-677
45. Siefer AK, Longo DL, Harrison CL, Reynolds CW, Murphy WJ (1993) Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice. Blood 82(8):2577-2584
46. Chen C, Busson M, Rocha V, Appert ML, Lepage V, Dulphy N et al (2006) Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 38(6):437-444
47. Stern M, Elsasser H, Honger G, Steiger J, Schaub S, Hess C (2008) The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am J Transplant 8(6): 1312-1317
48. Farrell HE, Vally H, Lynch DM, Fleming P, Shellam GR, Scalzo AA et al (1997) Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 386(6624): 510-514
49. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102(3):814-819
50. Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R et al (2005) Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodi fied allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 105(6):2594-2600
51. Lowe EJ, Turner V, Handgretinger R, Horwitz EM, Benaim E, Hale GA et al (2003) T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-nonidentical paediatric bone marrow transplantation. Br J Haematol 123(2):323-326
52. Clausen J, Kircher B, Auberger J, Schumacher P, Ulmer H, Hetzenauer G et al (2010) The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLAidentical siblings. Biol Blood Marrow Transplant 16(2):273-280
53. Linn YC, Phang CY, Lim TJ, Chong SF, Heng KK, Lee JJ et al (2010) Effect of missing killerimmunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients. Bone Marrow Transplant 45(6):1031-1037
54. Gagne K, Busson M, Bignon JD, Balere-Appert ML, Loiseau P, Dormoy A et al (2009) Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(11): 1366-1375
55. Triplett BM, Horwitz EM, Iyengar R, Turner V, Holladay MS, Gan K et al (2009) Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia 23(7):1278-1287
56. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT et al (2009) Donors with group B KIR haplotypes improve relapsefree survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113(3):726-732
57. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT et al (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116(14): 2411-2419
58. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR et al (2003) IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 32(2):177-186
59. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850-854
60. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR et al (2010) Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 59(11):1739-1744
61. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA et al (2010) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13(1):98-107
62. Cooley S, Gada P, McKenna D, McCullar V, Fautsch S, Verneris MR et al (2008) Successful haploidentical hematopoietic cell engraftment using a non-myeloablative preparative regimen including natural killer (NK) cells. In: American Society of Hematology 50th annual meeting, San Francisco, CA: Blood, p 827
63. Pfeiffer MM, Feuchtinger T, Teltschik HM, Schumm M, Muller I, Handgretinger R et al (2010) Reconstitution of NK cell receptors in fl uences NK activity and relapse rate after haploidentical transplantation of T and B cell depleted grafts in children. Haematologica 95(8):1381-1388
64. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T et al (2004) Puri fied donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18(11):1835-1838
65. Koehl U, Esser R, Zimmermann S, Tonn T, Kotchetkov R, Bartling T et al (2005) Ex vivo expansion of highly puri fied NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr 217(6): 345-350
66. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T et al (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28(6):955-959
67. Lugli E, Goldman CK, Perera LP, Smedley J, Pung R, Yovandich JL et al (2010) Transient and persistent effects of IL15 on lymphocyte homeostasis in nonhuman primates. Blood 116(17):3238-3248
68. Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D et al (2006) Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci USA 103(14): 5460-5465
69. Bordin JO, Heddle NM, Blajchman MA (1994) Biologic effects of leukocytes present in transfused cellular blood products. Blood 84(6):1703-1721
70. McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S et al (2007) Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 47(3):520-528
71. Miller JS, Oelkers S, Verfaillie C, McGlave P (1992) Role of monocytes in the expansion of human activated natural killer cells. Blood 80(9):2221-2229
72. Godal R, Bachanova V, Gleason M, McCullar V, Yun GH, Cooley S, Verneris MR, McGlave PB, Miller JS (2010) Natural killer cell killing of AML and ALL blasts by killer cell immunoglobulin-like receptor negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant 16(5): 612-621
73. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94(7):2208-2216
74. Reed M, Yearsley M, Krugh D, Kennedy MS (2003) Severe hemolysis due to passenger lymphocyte syndrome after hematopoietic stem cell transplantation from an HLA-matched related donor. Arch Pathol Lab Med 127(10): 1366-1368
75. Hummon D, Zantek ND, Sumstad D, Miller JS, McKenna DH (2009) Transfusion-associated graft-versus-host disease: a perspective from a cell therapy laboratory. Transfusion 49(5): 1018-1019
76. McKenna DH, Kadidlo DM, Miller JS, Orchard PJ, Wagner JE, McCullough J (2005) The Minnesota molecular and cellular therapeutics facility: a state-of-the-art biotherapeutics engineering laboratory. Transfus Med Rev 19(3): 217-228